Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.
P/S ratio for Longeveron Inc. (LGVN)
P/S ratio as of 2023: 41.69
According to Longeveron Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 41.69. At the end of 2022 the company had a P/S ratio of 55.25.
P/S ratio history for Longeveron Inc. from 2018 to 2023
P/S ratio at the end of each year
| Year | P/S ratio |
|---|---|
| 2023 | 41.69 |
| 2022 | 55.25 |
| 2021 | 174.81 |
| 2020 | 22.19 |
| 2019 | 21.05 |
| 2018 | 55.21 |